ASX:BOT Botanix Pharmaceuticals (BOT) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free BOT Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.63 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield2.96%Price TargetN/A Stock AnalysisStock Analysis Get Botanix Pharmaceuticals alerts: Email Address Ad Paradigm PressBiden to Drop BOMBSHELL June 13th?Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th!Click here now to see his shocking evidence. About Botanix Pharmaceuticals Stock (ASX:BOT)Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia.Read More Ad Paradigm PressBiden to Drop BOMBSHELL June 13th?Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th!Click here now to see his shocking evidence. BOT Stock News HeadlinesMay 15 at 10:30 PM | morningstar.comBotanix Pharmaceuticals Ltd BXPHFApril 30, 2024 | finance.yahoo.comWe're Keeping An Eye On Botanix Pharmaceuticals' (ASX:BOT) Cash Burn RateMarch 8, 2024 | wsj.comBotanix Pharmaceuticals Ltd.January 23, 2024 | investing.comBotanix Pharmaceuticals Ltd (BOT)January 23, 2024 | fool.com.auIf you'd put $40,000 in this ASX healthcare stock at the start of 2023, you'd have $128,000 nowDecember 14, 2023 | morningstar.comBotanix Pharmaceuticals Ltd BOTOctober 12, 2023 | finance.yahoo.comBotanix Pharmaceuticals (ASX:BOT) shareholders have earned a 138% return over the last yearSeptember 26, 2023 | fool.com.auGuess which ASX cannabis share is crashing 36% following an FDA blowSeptember 20, 2023 | fool.com.auThis ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!September 1, 2023 | finance.yahoo.comBotanix Pharmaceuticals Full Year 2023 Earnings: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)August 12, 2023 | finanznachrichten.deFresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 24, 2023 | benzinga.comWhat's Happening With Fresh Tracks Therapeutics (FRTX) SharesJuly 21, 2023 | benzinga.comWhy Fresh Tracks Therapeutics (FRTX) Shares Are SkyrocketingJune 30, 2023 | finance.yahoo.comBOT.AX - Botanix Pharmaceuticals LimitedMay 10, 2023 | technews.tmcnet.comFresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMarch 31, 2023 | finanznachrichten.deFresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateFebruary 20, 2023 | finance.yahoo.comBotanix Pharmaceuticals (ASX:BOT) adds AU$12m to market cap in the past 7 days, though investors from five years ago are still down 47%December 1, 2022 | finance.yahoo.comWe're A Little Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn RateNovember 11, 2022 | ca.finance.yahoo.comFresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 14, 2022 | fool.com.auInvesting in ASX cannabis sharesOctober 14, 2022 | seekingalpha.comRVLP RVL Pharmaceuticals plcSeptember 13, 2022 | finance.yahoo.comThe past three years for Botanix Pharmaceuticals (ASX:BOT) investors has not been profitableAugust 31, 2022 | afr.comBotanix Pharmaceuticals raising for its sweating treatmentAugust 11, 2022 | finance.yahoo.comEczema Clinical Trial Pipeline Insights | DelveInsightAugust 11, 2022 | finance.yahoo.comBrickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateSee More Headlines Receive BOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Botanix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2019Today5/16/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:BOT CUSIPN/A CIKN/A Webwww.botanixpharma.com Phone+61-8-94820580FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,020,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.25% Return on Assets-18.33% Debt Debt-to-Equity Ratio0.19 Current Ratio9.50 Quick Ratio1.26 Sales & Book Value Annual Sales$3.77 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.50 Book ValueA$0.03 per share Price / BookN/AMiscellaneous Outstanding Shares1,580,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.84 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Vincent P. Ippolito (Age 65)MD & Executive Chairman Comp: $364.85kDr. Howie McKibbonChief Executive OfficerMr. Matthew Callahan L.L.B. (Age 51)M.B.A., MBA LLB, Executive Director Comp: $385.52kDr. Jack Hoblitzell Ph.D.Senior Vice President of Pharmaceutical DevelopmentDr. Patricia S. Walker M.D. (Age 65)Ph.D., Chief Medical Adviser Ms. Susan Patricia Park A.C.A. (Age 49)A.C.I.S., ACSA, AGIA, B.Com., F Fin, FCIS,, Company Secretary More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersVince IppolitoSold 2,000,000 sharesTotal: $170,000.00 ($0.09/share) BOT Stock Analysis - Frequently Asked Questions How were Botanix Pharmaceuticals' earnings last quarter? Botanix Pharmaceuticals Limited (ASX:BOT) announced its quarterly earnings data on Thursday, February, 28th. The company reported ($0.01) earnings per share for the quarter. What other stocks do shareholders of Botanix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Botanix Pharmaceuticals investors own include Byron Energy (BYE), Harmony Gold Mining (HMY), Puhui Wealth Investment Management (PHCF), NIKE (NKE), Michael Hill International (MHJ), Lynas Rare Earths (LYC), Cobalt 27 Capital (KBLT), Eclipx Group (ECX) and Bod Australia (BDA). This page (ASX:BOT) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Botanix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.